ARDX
Ardelyx, Inc.
stock NASDAQ

For traders who like to surf news spikes instead of marry stories, these five biotechs are basically event machines with well defined triggers and clear failure points.
* NASDAQ: CRIS is a pure data trade into hematology meetings, strength comes on clean AML and CLL combo numbers, weakness below recent lows says step away until the next dataset.
* NASDAQ: ABVC is a licensing cash flow speculation, watch quarterly updates on payments from OncoX and AiBtl, any shortfall versus guidance is your exit cue.
* NASDAQ: ARDX is an execution chart, with beats on IBSRELA and XPHOZAH uptake as upside fuel, a miss or guidance cut likely resets the range lower.
* NASDAQ: MYNZ is a microcap attention play where OncoVanguard8 progress, eAArly DETECT 2 updates and conference exposure can send it vertical, but financing and dilution risk never leaves the room.
* NASDAQ: MIST is the closest thing to a near term binary ticket, all focus on the December PDUFA, where approval makes it a re rating candidate and a negative outcome turns it into a salvage story.

Small cap biotech is still throwing wild moves, and these five names have real catalysts lined up rather than just vibes.
* **NASDAQ: ARDX** around 5.5 is already commercial with IBSRELA and XPHOZAH, so the trade is execution plus label and geography expansion, with risk if launches miss and margins compress.
* **NASDAQ: BTAI** near 1.8 has IGALMI approved and late stage agitation programs, watch any sNDA progress and dementia data, but a failed expansion or more dilution kills the thesis under 1.40.
* **NASDAQ: CRIS** around 1.1 is an ASH data and combo trial story in AML and CLL, momentum only holds if emavusertib numbers impress.
* **NASDAQ: ABVC** near 2.7 leans on licensing revenue and milestones, any slip in partner cash flows is your red flag.
* **NASDAQ: MYNZ** at 1.06 is a microcap diagnostics vehicle for CRC and pancreatic tests, upside around South America and UK launches, downside if financing comes ugly or eAArly DETECT 2 stalls.

For traders who like to surf news spikes instead of marry stories, these five biotechs are basically event machines with well defined triggers and clear failure points.
* NASDAQ: CRIS is a pure data trade into hematology meetings, strength comes on clean AML and CLL combo numbers, weakness below recent lows says step away until the next dataset.
* NASDAQ: ABVC is a licensing cash flow speculation, watch quarterly updates on payments from OncoX and AiBtl, any shortfall versus guidance is your exit cue.
* NASDAQ: ARDX is an execution chart, with beats on IBSRELA and XPHOZAH uptake as upside fuel, a miss or guidance cut likely resets the range lower.
* NASDAQ: MYNZ is a microcap attention play where OncoVanguard8 progress, eAArly DETECT 2 updates and conference exposure can send it vertical, but financing and dilution risk never leaves the room.
* NASDAQ: MIST is the closest thing to a near term binary ticket, all focus on the December PDUFA, where approval makes it a re rating candidate and a negative outcome turns it into a salvage story.

Small cap biotech is still throwing wild moves, and these five names have real catalysts lined up rather than just vibes.
* **NASDAQ: ARDX** around 5.5 is already commercial with IBSRELA and XPHOZAH, so the trade is execution plus label and geography expansion, with risk if launches miss and margins compress.
* **NASDAQ: BTAI** near 1.8 has IGALMI approved and late stage agitation programs, watch any sNDA progress and dementia data, but a failed expansion or more dilution kills the thesis under 1.40.
* **NASDAQ: CRIS** around 1.1 is an ASH data and combo trial story in AML and CLL, momentum only holds if emavusertib numbers impress.
* **NASDAQ: ABVC** near 2.7 leans on licensing revenue and milestones, any slip in partner cash flows is your red flag.
* **NASDAQ: MYNZ** at 1.06 is a microcap diagnostics vehicle for CRC and pancreatic tests, upside around South America and UK launches, downside if financing comes ugly or eAArly DETECT 2 stalls.